PharmaCyte Biotech Other Current Liabilities

PharmaCyte Biotech (PMCB) currently reports a other current liabilities of $560B as of April 2026. That compares with $2.5M in the prior-year period — up 22079595.3% year over year. Use the charts on this page to explore PharmaCyte Biotech's other current liabilities history and peer comparisons.

PharmaCyte Biotech's other current liabilities increased from $2.5M to $560B — a 22079595.3% year-over-year increase (period ending April 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

PharmaCyte Biotech reported $560B in other current liabilities as of April 2026. That compares with $2.5M in the prior-year period — up 22079595.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $560B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for PharmaCyte Biotech, and consider following PMCB for alerts when major investors trade the stock.

PharmaCyte Biotech is classified in the Healthcare sector. On other current liabilities, it currently shows $560B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PMCB with unrelated industries.